Table 1.

The comparison between allogenic CAR-T cell therapy and autologous CAR-T cell therapy.

	Allogeneic CAR-T therapy	Autologous CAR-T therapy
Manufacturing process
Cell Source	Healthy donor	Patient (recipient)
Expansion capacity	High	Limited
Off-the-Shelf Availability	Standardized product	Customized for each patient, limited off-the-shelf availability
Possibility of T-cell phenotype selection	High	Limited
Quality of original T cells	High	Low
Time of accessibility	Readily available	Time-consuming, possible for manufacturing failure
Treatment
Requirement for lymphodepletion	Enhanced lymphodepletion regimen, or standard lymphodepletion regimen (with additional HLA depletion)	Standard lymphodepletion regimen
Flexibility in dosing	Flexible for redosing or changes of target	Limited flexibility as the dose is dependent on the patient's ability to yield sufficient T cells
In vivo persistence	Short (days to months)	Long (months to years)
Side effects
GVHD	High risk	Low risk
Immunogenicity (HVGR)	Possible	Lower risk
CRS and ICANS	Yes	Yes
Cost	Lower	Expensive, upwards to US$350,000